How Trenbolone Affects TSH and Thyroid Function

Androgens suppress the hepatic synthesis of thyroxine-binding globulin (TBG), the carrier protein for circulating thyroid hormones. With less TBG available, a larger fraction of total T3 and T4 exists in the free (unbound) form, and total measured levels fall because the protein-bound pool shrinks.

This effect was established in controlled studies:

1. Small et al. (1984) administered stanozolol to healthy males and documented decreased total T4 and T3 with decreased TBG, while free T4 and TSH remained unchanged. This dissociation between total and free fractions is the defining fingerprint of TBG suppression.

2. Deyssig and Weissel (1993) studied bodybuilders using approximately 1.2 g/week of mixed AAS and confirmed the same pattern: total T4 and T3 significantly decreased, TBG significantly reduced, while basal TSH and free T4 showed no significant changes.

3. Alen et al. (1987) found TSH, T4, T3, and TBG all decreased in AAS-using power athletes, with the critical observation that TBG was the primary target of androgen action.

Trenbolone's high androgen receptor binding affinity (comparable to DHT) means it may suppress TBG more aggressively than equivalent doses of weaker androgens. The effect is dose-dependent and fully reversible after cessation.

TSH is the most reliable screening marker because it reflects the pituitary's assessment of free thyroid hormone availability. A normal TSH means the pituitary does not detect a deficit, regardless of how low total T3 or T4 appear on the panel.

Total T3 and total T4:

• Decreased 15-40% from baseline due to TBG suppression
• The decrease is proportional to androgen dose and potency
• Trenbolone's high androgenic potency may produce more pronounced total T3/T4 depression than equivalent testosterone doses

Free T3 and free T4:

• Typically remain within normal range
• May show slight redistribution effects but do not fall proportionally with totals

TSH:

• Remains normal (0.5-4.5 mIU/L) in most users
• Normal TSH rules out true hypothyroidism regardless of total T3/T4 levels
• TSH above 10 mIU/L on cycle warrants further investigation (likely unrelated to AAS)

TBG (if tested):

• Decreased, proportional to androgen dose
• Confirms the mechanism if there is clinical doubt

Order TSH as your primary thyroid screening marker on trenbolone. It is unaffected by TBG suppression and reliably reflects actual thyroid status.

If TSH is normal: No further thyroid investigation is needed regardless of total T3/T4 values.

If you want confirmation beyond TSH: Order free T3 and free T4 (not total panels). These reflect biologically active thyroid hormone and are less confounded by TBG changes.

Do not order total T3 or total T4 as your primary thyroid assessment on AAS. They will almost always read low and provide no useful clinical information.

Timing: Baseline and mid-cycle (week 6-8) are sufficient. Thyroid function tests are not needed at every blood draw.

• Do not start exogenous T3 (Cytomel, liothyronine) based on low total T3 while on trenbolone. Adding T3 when free thyroid hormone is already adequate risks thyrotoxicosis and long-term thyroid suppression
• If you experience genuine hypothyroid symptoms (persistent fatigue, significant cold intolerance, bradycardia, constipation, mental fog) with a normal TSH, investigate non-thyroidal causes first: caloric deficit, poor sleep, overtraining, and psychological stress all produce similar symptoms on cycle
• Low total T3 with normal TSH during contest prep is virtually guaranteed: caloric restriction, high training volume, and AAS all independently suppress total T3. This is adaptive, not pathological
• All documented thyroid alterations from AAS in the literature normalised completely after cessation